Samsung Bioepis Reports Real-World Data of Benepali (biosimilar, etanercept) in Patients with Psoriasis at EADV 2019

 Samsung Bioepis Reports Real-World Data of Benepali (biosimilar, etanercept) in Patients with Psoriasis at EADV 2019

C-Bridge Capital Signs a Development & Commercialization Agreement with Samsung Bioepis for Biosimilars in China

Shots:

  • The study enrolled BADBIR-registered patient treated with Benepali from Jan 01, 2016 to Sept 01, 2018. BADBIR is a UK and Ireland observational study assessing long-term safety of biologic treatments for psoriasis while Samsung Bioepis participated in it since May 2016
  • The mean disease duration was 22.6 yrs., PASI and DLQI scores 11.6 and 13.1 respectively, median treatment period 14.1 months. In 48 patients with PASI score at baseline and 6 mos. PASI < 10 (N=20, mean PASI 3.2) no increment after 6 mos. and PASI ≥ 10 (N=28, mean PASI 15.7) reduced after 6 mos. (mean PASI 5.0)
  • Benepali (biosimilar, etanercept) referencing Enbrel is an anti-TNF biosimilar approved by EC in Jan 2016, for moderate to severe RA, JIA, PsA, axSpA  (ankylosing spondylitis and non-radiographic axial spondyloarthritis), and plaque psoriasis and is available in 25 countries in EU plus most prescribed across France, Germany, Italy, Spain, and the UK combined

Click here to­ read full press release/ article | Ref: Samsung Bioepis | Image: Twitter

Shiwani Sharma

Shiwani Sharma is a Senior Editor at PharmaShots. She has in-depth knowledge of lifesciences industry including pharma and biotech sectors. She also covers news in field of Digital Health, Medtech and regulatory approvals from the US FDA, EU, and other global regulatory bodies in the industry. Additionally, she also writes Whitepapers, analysis reports, blogs on pharma and biotech industry. She is graduate in Biotechnology. She can be contacted on shiwani@pharmashots.com

Related post